Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced-Toxicity Conditioning Regimen for Blast Phase Chronic Myeloid Leukemia
NCT07259161Phase 2Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Dec 2025
- Primary completion
- Sep 2029
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
01
Overview
A Phase 2 trial of thiotepa, melphalan, fludarabine in chronic myeloid leukemia (CML), sponsored by Institute of Hematology and Blood Diseases Hospital. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
thiotepamelphalanfludarabine
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT07259161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07259161.